Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension studyHeinz Gisslinger, Jiřı́ Schwarz, Róbert Královics et al.|The Lancet Haematology|2020Cited by 351